Patents Examined by Gerald G Leffers, Jr.
  • Patent number: 8614091
    Abstract: In certain aspects, the present invention provides methods and compositions relating to a Pnmt-positive progenitor cell. In certain aspects, the present invention relates to methods for isolating and transplanting the subject progenitor cells, and methods for treating diseases such as myocardiac injuries and neurodegenerative disorders.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: December 24, 2013
    Inventors: Steven N. Ebert, Karl Pfeifer
  • Patent number: 6759231
    Abstract: A &lgr; phage with a nuclear localization signal has been obtained by constructing a vector capable of expressing a fused protein between a gpD protein constituting the head of a &lgr; phage and a nuclear localization signal sequence, transforming Escherichia coli with this vector, and propagating a mutant &lgr; phage which cannot express the gpD protein in E. coli in this transformant. It has been confirmed that the resulting &lgr; phage is capable of packaging &lgr; phage DNAs of 80% and 100% genome sizes. After further confirming that the nuclear localization signal exposed on the outside of the head of this phage, this phage has been microinjected into cells to analyze its nuclear localization activity. Thus, it has been clarified that this phage has a nuclear localization activity.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: July 6, 2004
    Assignee: Dnavec Research Inc.
    Inventors: Mahito Nakanishi, Emi Nagoshi, Teruo Akuta, Katsuo Takeda, Mamoru Hasegawa
  • Patent number: 6743620
    Abstract: The present invention provides a process for preparing a retrovirus to be expressed at a high titer by specifically transferring a desired foreign gene into target cells. A pseudotyped retrovirus vector having a high titer can be prepared by transferring a DNA construction wherein a promoter, an loxP sequence, a VSV-G gene and a polyA addition signal are arranged in this order is transferred into cells carrying the retrovirus gag and pol gene expression systems, and then transferring a retrovirus vector containing the desired foreign gene thereinto, followed by treatment with a recombinase.
    Type: Grant
    Filed: January 5, 1999
    Date of Patent: June 1, 2004
    Assignee: Eisai Co., Ltd.
    Inventors: Hideo Iba, Tohru Arai
  • Patent number: 6730499
    Abstract: The present invention provides formaldehyde dehydrogenase genes (FLD) from methylotrophic yeasts. The FLD structural genes confer resistance to formaldehyde and are therefore useful as a selectable marker in methylotrophic yeasts. The FLD promoter sequences are strongly and independently induced by either methanol as sole carbon source (with ammonium sulfate as nitrogen source) or methylamine as sole nitrogen source (with glucose as carbon source). Induction under either methanol, methylamine or both provides levels of heterologous gene expression comparable to those obtained with the commonly used alcohol oxidase I gene promoter (PAOX1). The FLD promoter of Pichia pastoris (PFLD1)is an attractive alternative to PAOX1 for expression of foreign genes in P. pastoris, allowing regulation by carbon (methanol) or nitrogen (methylamine) source within the same expression strain.
    Type: Grant
    Filed: July 2, 1999
    Date of Patent: May 4, 2004
    Assignee: Research Corporation Technologies, Inc.
    Inventor: James M. Cregg
  • Patent number: 6716601
    Abstract: The invention provides novel yeast promoters useful for controlling the expression of homologous and heterologous nucleic acid molecules in yeast cells. The yeast promoters are induced by a fermentable carbon source, such as glucose, or a non-fermentable carbon source, such as ethanol, or both. Therefore, expression of nucleic acid molecules encoding a polypeptide under the control of the novel yeast promoters may be regulated by varying the level of a fermentable carbon source, or a non-fermentable carbon source, or both.
    Type: Grant
    Filed: January 8, 2001
    Date of Patent: April 6, 2004
    Assignee: AstraZeneca AB
    Inventors: Graham P Belfield, Caroline Oakley
  • Patent number: 6699702
    Abstract: The invention relates to a prokaryotic cell system for monitoring protease activity. The invention also includes assays for identifying protease inhibitors and protease modulators, determining the amino acid sequence of a protease cleavage site for a known protease, identifying and cloning a protease whose cleavage site is known, and rapidly identifying a form of a protease exhibiting increased activity relative to a control protease.
    Type: Grant
    Filed: January 6, 2000
    Date of Patent: March 2, 2004
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Pramathesh Patel, David Lach
  • Patent number: 6696278
    Abstract: The present invention provides a method of transfer of a gene of interest from a first vector to a product vector comprising contacting a first and second vector in vitro with a site-specific recombinase so as to generate a co-integrate vector comprising the components of the first and second vector, and introducing the co-integrate vector to a prokaryotic host cell so as to generate a product vector by rolling circle replication, comprising the gene of interest.
    Type: Grant
    Filed: February 26, 2001
    Date of Patent: February 24, 2004
    Assignee: Stratagene
    Inventor: Carsten-Peter Carstens
  • Patent number: 6696287
    Abstract: The present invention is directed to an apparatus that can be used for co-culturing bacteria and eukaryotic cells. The apparatus allows the bacteria to be grown under steady state conditions and then perfused over the eukaryotic cells. The invention also includes a variety of methods for studying the attachment and invasion of host eukaryotic cells by bacteria.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: February 24, 2004
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Lawrence C. Paoletti, Gennady Malin
  • Patent number: 6696282
    Abstract: The instant invention is drawn towards transformed strains of Fusarium sporotrichioides effective for the production of lycopene. The transformed strains comprise an expression cassette having three genes encoding, respectively, geranylgeranyl-pyrophosphate synthase, phytoene synthase and phytoene desaturase (i.e. Tri5crtE, Tri5crtB and Tri5crtl). The transformed strains of Fusarium sporotrichioides of the instant invention produce lycopene at levels of up to 0.5 milligrams per gram culture dry weight.
    Type: Grant
    Filed: January 14, 2002
    Date of Patent: February 24, 2004
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: James D. Jones, Thomas M. Hohn, Timothy D. Leathers
  • Patent number: 6696295
    Abstract: The present invention is directed to isolated transducing phages, methods of isolating transducing phages, and methods of using transducing phages including, for instance, transferring at least one nucleic acid fragment from a donor microbe to a recipient microbe, and producing a secondary metabolite from a microbe. The transducing phages typically have a broad host range, and transduce microbes in the Order Actinomycetales, in particular in the Family Streptomycetaceae, including Streptomyces coelicolor, Streptomyces lividans, Streptomyces venezuelae, Streptomyces avermitilis, and Saccharopolyspora erythraea. The transducing phages can be specialized transducing phages or generalized transducing phages.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: February 24, 2004
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Janet Westpheling, Julie A. Burke
  • Patent number: 6692942
    Abstract: The present invention is directed to a method of in vivo and ex vivo gene delivery, for a variety of cells. More specifically, it relates to a novel carrier system and method for targeted delivery of nucleic acids to mammalian cells. More specifically, the present invention relates to carrier system comprising single-chain polypeptide binding molecules having an a region rich in basic amino acid and having the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. The basic amino acid rich region can comprise oligo-lysine, oligo-arginine or combinations thereof. Such preparations of modified single chain polypeptide binding molecules also have ability to bind nucleic acids at the region rich in basic amino acid residues. These properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications including gene therapy.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: February 17, 2004
    Assignee: Enzon, Inc.
    Inventors: David R. Filpula, Maoliang Wang, Marc D. Whitlow
  • Patent number: 6686166
    Abstract: Specific genetic deletions are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: February 3, 2004
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael A. Wilson
  • Patent number: 6677139
    Abstract: The present invention provides methods for the production of proteins, particularly toxic proteins, in host cells. The invention provides methods which use a fusion protein comprising a chaperonin binding domain in host cells induced or regulated to have increased levels of chaperonin which binds the chaperonin binding domain.
    Type: Grant
    Filed: December 23, 1999
    Date of Patent: January 13, 2004
    Assignee: Genecor International, Inc.
    Inventors: Mark Donnelly, Andrzej Joachimiak
  • Patent number: 6589741
    Abstract: The present invention relates to methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules. The method of the present invention is particularly characterized by an in vitro translation step under conditions that allow formation of polysomes in the presence of antisense oligonucleotides complementary to the tag-coding sequence of ssrA-RNA. The present invention further relates to kits that are useful for carrying out the method of the invention.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: July 8, 2003
    Assignee: University of Zurich
    Inventors: Andreas Plückthun, Jozef Hanes, Lutz Jermutus
  • Patent number: 6586240
    Abstract: A method for visualizing the location and movement of a specific RNA of interest in a living cell, in real time, is disclosed. The method includes the following steps: (a) providing a DNA encoding the RNA, which RNA includes a protein-binding site; (b) providing a nucleic acid encoding a fusion protein, which fusion protein comprises a fluorescent domain and an RNA-binding domain; (c) introducing the DNA encoding the RNA, and the nucleic acid encoding the fusion protein, into a eukaryotic cell so that the DNA encoding the RNA and the nucleic acid encoding the fusion protein are expressed in the cell; and (d) detecting fluorescence outside the nucleus or inside the nucleus of the cell, with the fluorescence being from the fusion protein bound to the RNA. In some embodiments, the fusion protein also includes an intracellular localization domain.
    Type: Grant
    Filed: September 6, 2000
    Date of Patent: July 1, 2003
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Robert H. Singer, Edouard Bertrand
  • Patent number: 6582960
    Abstract: The present invention provides an improved method for expanding cells for use in tissue engineering. In particular the method provides specific biochemical factors to supplement cell culture medium during the expansion process in order to reproduce events occurring during embryonic development with the goal of regenerating tissue equivalents that resemble natural tissues both structurally and functionally. These specific biochemical factors improve proliferation of the cells and are capable of de-differentiation mature cells isolated from tissue so that the differentiation potential of the cells is preserved. The bioactive molecules also maintain the responsiveness of the cells to other bioactive molecules. Specifically, the invention provides methods for expanding chondrocytes in the presence of fibroblast growth factor 2 for use in regeneration of cartilage tissue.
    Type: Grant
    Filed: September 17, 1999
    Date of Patent: June 24, 2003
    Assignee: Massachusetts Institute of Technology
    Inventors: Ivan Martin, Lisa E. Freed, Robert Langer, Gordana Vunjak-Novakovic
  • Patent number: 6576456
    Abstract: The invention provides a chimeric adenovirus fiber protein including a nonnative amino acid sequence, and a chimeric adenovirus fiber protein lacking a native amino acid receptor-binding sequence. The chimeric protein trimerizes when produced in a mammalian cell.
    Type: Grant
    Filed: June 4, 1999
    Date of Patent: June 10, 2003
    Assignees: Cornell Research Foundation, Inc., GenVec, Inc.
    Inventors: Thomas J. Wickham, Erik Falck-Pedersen, Petrus W. Roelvink, Joseph T. Bruder, Jason Gall, Imre Kovesdi
  • Patent number: 6569679
    Abstract: The present invention provides recombinant viral vectors carrying a vector construct which directs the expression of a gene product (e.g., HSVTK) that activates a compound with little or no cytotoxicity into a toxic product. Also provided are methods of destroying or inhibiting pathogenic agents in a warm blooded animal, comprising the step of administering to the animal a viral vector such as that described above, in order to inhibit or destroy the pathogenic agent.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 27, 2003
    Assignee: Chiron Corporation
    Inventors: Jack R. Barber, Harry E. Gruber, Douglas J. Jolly
  • Patent number: 6562595
    Abstract: The present invention provides a novel dominant selectable marker system in yeast that is based on an aminoglycoside, nourseothricin (NST). This compound possesses a powerful antifungal activity against Candida albicans and S. cerevisiae. The invention provides a cognate drug resistance marker for use in gene transformation and disruption experimentation in Candida albicans and Saccharomyces cerevisiae. In particular, the invention presents: 1) direct utility for gene manipulations in both clinically and experimentally relevant strains regardless of genotype and without affecting growth rate, or hyphal formation; and 2) applicability to antifungal drug discovery, including target validation and various forms of drug screening assays.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: May 13, 2003
    Assignee: McGill University
    Inventors: Terry Roemer, Howard Bussey, John Davison
  • Patent number: 6548274
    Abstract: The present invention relates to methods for producing a polypeptide, comprising: (a) cultivating a fungal host cell in a medium conducive for the production of the polypeptide; and (b) isolating the polypeptide from the cultivation medium; wherein the fungal host cell comprises a first nucleic acid sequence encoding the polypeptide in tandem with a second nucleic acid sequence comprising a crippled translational initiator sequence operably linked to a gene encoding a selectable marker, wherein the copy number of the first nucleic acid sequence has been increased by culturing the cell under conditions that select for multiple copies of the selectable marker. The present invention also relates to such fungal host cells and methods for obtaining such fungal host cells. The present invention further relates to nucleic acid constructs and vectors comprising a crippled translational initiator sequence operably linked to a gene encoding a selectable marker.
    Type: Grant
    Filed: January 12, 2001
    Date of Patent: April 15, 2003
    Assignee: Novozymes Biotech, Inc.
    Inventors: Debbie S. Yaver, Daniel A. Bellini